Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/173023
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Background: Inherited CDKN2A mutation is a strong risk factor for cutaneous melanoma. Moreover, carriers have been found to have poor melanoma-specific survival. In this study, responses to novel immunotherapy agents in CDKN2A mutation carriers with metastatic melanoma were evaluated. Methods: CDKN2A mutation carriers that have developed metastatic melanoma and undergone immunotherapy treatments were identified among carriers enrolled in follow-up studies for familial melanoma. The carriers' responses were compared with responses reported in phase III clinical trials for CTLA-4 and PD-1 inhibitors. From publicly available data sets, melanomas with somatic CDKN2A mutation were analysed for association with tumour mutational load. Results: Eleven of 19 carriers (58%) responded to the therapy, a significantly higher frequency than observed in clinical trials (p=0.03, binomial test against an expected rate of 37%). Further, 6 of the 19 carriers (32%) had complete response, a significantly higher frequency than observed in clinical trials (p=0.01, binomial test against an expected rate of 7%). In 118 melanomas with somatic CDKN2A mutations, significantly higher total numbers of mutations were observed compared with 761 melanomas without CDKN2A mutation (Wilcoxon test, p<0.001). Conclusion: Patients with CDKN2A mutated melanoma may have improved immunotherapy responses due to increased tumour mutational load, resulting in more neoantigens and stronger antitumorous immune responses.
Matèries
Matèries (anglès)
Citació
Col·leccions
Citació
HELGADOTTIR, Hildur, GHIORZO, Paola, VAN DOORN, Remco, PUIG I SARDÀ, Susana, LEVIN, Max, KEFFORD, Richard, LAUSS, Martin, QUEIROLO, Paola, PASTORINO, Lorenza, KAPITEIJN, Ellen, POTRONY MATEU, Míriam, CARRERA ÁLVAREZ, Cristina, OLSSON, Håkan, HÖIOM, Veronica, JÖNSSON, Göran. Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations. _Journal of Medical Genetics_. 2020. Vol. 57, núm. 5, pàgs. 316-321. [consulta: 20 de gener de 2026]. ISSN: 0022-2593. [Disponible a: https://hdl.handle.net/2445/173023]